

Antonio Tursi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/367334/antonio-tursi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

2,851
citations

30
h-index

48
g-index

161
ext. papers

3,312
ext. citations

3.4
avg, IF

5.67
L-index

#	Paper	IF	Citations
147	Diverticular Inflammation and Complication Assessment (DICA) Classification 2022 , 183-197		
146	The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study. <i>Annals of Gastroenterology</i> , 2021 , 34, 208-213	2.2	3
145	Omalizumab-induced colitis. <i>Digestive and Liver Disease</i> , 2021 , 53, 1356-1358	3.3	0
144	Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 670-679	2.2	4
143	Histological Remission in Ulcerative Colitis in Deep Remission under Treatment with Adalimumab. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021 , 30, 55-58	1.4	0
142	Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis Associated With Diverticulosis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1760-1761	0.7	1
141	The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: a single-center colonoscopy-based cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	3
140	SARS-COV-2 infection might cause transient cutaneous lesions in IBD patients under treatment with adalimumab. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021 , 30, 310-311	1.4	1
139	Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care. <i>Reviews on Recent Clinical Trials</i> , 2021 , 16, 329-334	1.2	0
138	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 205-206	6.9	
137	Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1399-1400	1.5	2
136	Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1462-1464	2.2	
135	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-8	5.4	
134	Performances of anti-TNF antibodies as long-term maintenance therapy for ulcerative colitis.. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, e1107-e1108	2.2	
133	Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 859-860	6.1	1
132	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820968747	4.7	1
131	Anti-TNF Agents in Inflammatory Bowel Disease and Course of COVID-19. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e73	4.5	18

130	Colonic diverticular disease. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 20	51.1	40
129	COVID-19 infection in Crohn's disease under treatment with adalimumab. <i>Gut</i> , 2020 , 69, 1364-1365	19.2	40
128	Diet in colonic diverticulosis: is it useful?. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 232-239	1.9	2
127	Incidental Schwannoma of the Sigmoid. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 303	1.4	
126	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1767-1776	4	5
125	Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1722-1724	0.7	9
124	INTESTINAL MICROBIOME MODULATION DURING COVID-19: ANOTHER CHANCE TO MANAGE THE DISEASE?. <i>Gastroenterology</i> , 2020 ,	13.3	3
123	Immune checkpoint inhibitors-induced acute diverticulitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 893-895	2.2	0
122	Risk factors for endoscopic severity of diverticular disease of the colon and its outcome: a real-life case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1123-1129	2.2	4
121	Impact of Anti-TNF Antibodies on the Risk of Covid-19 and its Severity in Patients with Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1646-1647	1.5	4
120	Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. <i>European Journal of Internal Medicine</i> , 2019 , 66, 85-91	3.9	12
119	Role of Inflammation in the Pathogenesis of Diverticular Disease. <i>Mediators of Inflammation</i> , 2019 , 2019, 8328490	4.3	16
118	Gitelman syndrome triggered by proton-pump inhibitor use. <i>Digestive and Liver Disease</i> , 2019 , 51, 911	3.3	0
117	Current and Evolving Concepts on the Pathogenesis of Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 225-235	1.4	11
116	Pathogenesis of Diverticulosis and Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 7-10	1.4	7
115	Acute Diverticulitis Is at Significant Risk of Malnutrition: an Analysis of Hospitalized Patients in a Medicine Department. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 53-56	1.4	3
114	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 57-66	1.4	7
113	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 39-44	1.4	0

112	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 11-16	1.4	0
111	What's New in Diagnosing Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 17-22	1.4	1
110	Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. <i>Annals of Gastroenterology</i> , 2019 , 32, 392-399	2.2	7
109	Diverticulosis today. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 42-52	1.6	1
108	The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 23-27	1.4	1
107	Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 45-48	1.4	1
106	Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 49-52	1.4	0
105	Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	0
104	Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. <i>Journal of Investigative Medicine</i> , 2019 , 67, 767-770	2.9	10
103	Effectiveness and Safety of Pylera [®] in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. <i>Digestive Diseases</i> , 2018 , 36, 264-268	3.2	14
102	A critical appraisal of advances in the diagnosis of diverticular disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 791-796	4.2	4
101	Efficacy and safety of a new nutraceutical formulation in managing patients with symptomatic uncomplicated diverticular disease: a 12-month, prospective, pilot study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018 , 27, 201-202	1.4	5
100	Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018 , 27, 291-297	1.4	15
99	No changes in Interleukin-10 expression in symptomatic uncomplicated diverticular disease of the colon. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018 , 27, 476-477	1.4	2
98	Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. <i>Medicine (United States)</i> , 2018 , 97, e11897	1.8	15
97	Symptomatic Uncomplicated Diverticular Disease: Chronic Abdominal Pain in Diverticulosis Is Not Enough to Make the Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 2001-2002	6.9	8
96	The Pathophysiology of Colonic Diverticulosis: Inflammation versus Constipation?. <i>Inflammatory Intestinal Diseases</i> , 2018 , 3, 55-60	2.5	3
95	Rectal Dieulafoy lesion. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, 1-2	2.4	4

94	TNFSF15 Polymorphism and Diverticulitis of the Colon: Another Step Toward a More Tailored Approach in a Complex Disease. <i>Annals of Surgery</i> , 2017 , 265, e33	7.8	2
93	New bismuth-containing quadruple therapy in patients infected with <i>Helicobacter pylori</i> : A first Italian experience in clinical practice. <i>Helicobacter</i> , 2017 , 22, e12371	4.9	27
92	Primary gastro-duodenal acute myeloid leukemia presenting as persisting vomiting. <i>Digestive and Liver Disease</i> , 2017 , 49, 576-577	3.3	
91	Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, 344-346	2.4	3
90	Dietary pattern and colonic diverticulosis. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2017 , 20, 409-413	3.8	8
89	Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in Italy. <i>Annals of Translational Medicine</i> , 2017 , 5, 320	3.2	5
88	Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2017 , 26, 239-244	1.4	23
87	Management of diverticulosis: what's new?. <i>Minerva Medica</i> , 2017 , 108, 448-463	2.2	10
86	Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real-life experience in IBD primary centers. <i>Minerva Gastroenterology</i> , 2017 , 63, 313-318	3	6
85	Persistence of endoscopic rectal inflammation in UC treated with infliximab is not linked to ineffective TNF α downregulation. <i>Gut</i> , 2016 , 65, 539-40	19.2	1
84	Management of Patients With Diverticulosis and Diverticular Disease: Consensus Statements From the 2nd International Symposium on Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S101-7	3	21
83	Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S9-S12	3	50
82	Preface to the Proceedings of the 2nd International Symposium on Diverticular Disease of the Colon. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S1	3	2
81	Prognostic Role of the Endoscopic Classification "DICA". <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S16-9	3	4
80	Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, e61-e63	2.4	8
79	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016 , 4, 604-13	5.3	24
78	Prucalopride for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 351	3	5
77	Diverticulosis today: unfashionable and still under-researched. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 213-28	4.7	61

76	Macronodular Finding of Small Bowel as a Sign of Common Variable Immunodeficiency. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 7	1.4	1
75	Mesalazine in preventing acute diverticulitis occurrence: a meta-analysis of randomized controlled trials. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 409-11	1.4	4
74	Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis. <i>Annals of Gastroenterology</i> , 2016 , 29, 24-32	2.2	23
73	Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S64-9	3	45
72	Current Management of Patients With Diverticulosis and Diverticular Disease: A Survey From the 2nd International Symposium on Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S97-S100	3	11
71	Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. <i>Digestive and Liver Disease</i> , 2016 , 48, 1511-1512	3.3	19
70	Serum levels of vitamin D are associated with the severity of the endoscopic appearance of diverticular disease of the colon according to DICA classification. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 567-568	1.4	4
69	Diverticular disease of the colon and irritable bowel syndrome: it is time to differentiate. <i>American Journal of Gastroenterology</i> , 2015 , 110, 774-5	0.7	13
68	Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. <i>Digestive Diseases</i> , 2015 , 33, 68-76	3.2	46
67	Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 218-21	3	53
66	New medical strategies for the management of acute diverticulitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1293-304	4.2	5
65	Interactions between Innate Immunity, Microbiota, and Probiotics. <i>Journal of Immunology Research</i> , 2015 , 2015, 501361	4.5	53
64	Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNF Antagonists. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1406-13	4	7
63	Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, 107-13	2.4	10
62	The role of colonoscopy in managing diverticular disease of the colon. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2015 , 24, 85-93	1.4	17
61	New physiopathological and therapeutic approaches to diverticular disease: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1005-17	4	21
60	Chronic diverticulitis and Crohn's disease share the same expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor- α . <i>Journal of Clinical Pathology</i> , 2014 , 67, 844-6	3.9	4
59	Increased faecal calprotectin predicts recurrence of colonic diverticulitis. <i>International Journal of Colorectal Disease</i> , 2014 , 29, 931-5	3	20

58	Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. <i>European Journal of Internal Medicine</i> , 2014 , 25, 485-90	3.9	11
57	Why perform colonoscopy following acute diverticulitis of the colon?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014 , 28, 3260-2	5.2	1
56	Managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers: similarities and differences. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, E24-5	4.5	
55	Efficacy, safety, and applicability of outpatient treatment for diverticulitis. <i>Drug, Healthcare and Patient Safety</i> , 2014 , 6, 29-36	1.6	11
54	Noninvasive prediction of chronic atrophic gastritis in autoimmune thyroid disease in primary care. <i>Scandinavian Journal of Gastroenterology</i> , 2014 , 49, 1394-6	2.4	4
53	Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. <i>European Journal of Internal Medicine</i> , 2014 , 25, 757-61	3.9	14
52	Histological inflammation in Crohn's disease in deep remission during treatment with anti-TNF α . <i>Digestive and Liver Disease</i> , 2014 , 46, 575-6	3.3	2
51	Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor- α in Crohn's disease in deep remission under treatment with anti-TNF α antibodies. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2014 , 23, 261-5	1.4	5
50	Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy. <i>Annals of Gastroenterology</i> , 2014 , 27, 369-373	2.2	15
49	Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study. <i>Gastroenterology</i> , 2013 , 17, 3244-8	13.3	6
48	Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting. <i>European Journal of Internal Medicine</i> , 2013 , 24, 852-6	3.9	19
47	Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 1359-60	2.4	5
46	Preventing recurrent acute diverticulitis with pharmacological therapies. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 277-86	4.9	8
45	Mesalazine in treating diverticular disease of the colon. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013 , 7, 409-12	4.2	
44	Endoscopic diagnosis of appendicitis. <i>Internal Medicine</i> , 2013 , 52, 1141	1.1	
43	Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013 , 22, 13-9	1.4	11
42	Long-lasting unspecific intestinal inflammation in ankylosing spondylitis evolving into Crohn's disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013 , 22, 472-3	1.4	
41	Segmental colitis associated with diverticulosis: a 5-year follow-up. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 179-85	3	21

40	Biomarkers in diverticular diseases of the colon. <i>Digestive Diseases</i> , 2012 , 30, 12-8	3.2	33
39	Advances in the management of colonic diverticulitis. <i>Cmaj</i> , 2012 , 184, 1470-6	3.5	15
38	Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant <i>Helicobacter pylori</i> infection. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012 , 21, 133-8	1.4	9
37	Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis is related to the severity of the endoscopic damage. <i>Digestive and Liver Disease</i> , 2011 , 43, 374-9	3.3	7
36	Efficacy, tolerability, and factors affecting the efficacy of the sequential therapy in curing <i>Helicobacter pylori</i> infection in clinical setting. <i>Journal of Investigative Medicine</i> , 2011 , 59, 917-20	2.9	14
35	Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity?. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 27-34	4	72
34	Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 3112-21	4	16
33	Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis down-regulates after treatment. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2011 , 20, 365-70	1.4	4
32	Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2218-27	0.7	320
31	Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 702-6	3	37
30	Celiac disease and viral B hepatitis: lessons for clinical practice. <i>Hepatitis Monthly</i> , 2010 , 10, 311-2	1.8	2
29	Balsalazide in treating colonic diseases. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 1555-63	5.3	4
28	Faecal calprotectin in colonic diverticular disease: a case-control study. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 49-55	3	86
27	Complications in celiac disease under gluten-free diet. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 2175-82	4	20
26	Assessment and grading of mucosal inflammation in colonic diverticular disease. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42, 699-703	3	70
25	Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42 Suppl 3 Pt 1, S119-22	3	9
24	The clinical picture of uncomplicated versus complicated diverticulitis of the colon. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 2474-9	4	52
23	Effect of gluten-free diet on pregnancy outcome in celiac disease patients with recurrent miscarriages. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 2925-8	4	22

22	Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. <i>Hepato-Gastroenterology</i> , 2008 , 55, 916-20		12
21	Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 671-4	4	42
20	Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. <i>International Journal of Colorectal Disease</i> , 2007 , 22, 1103-8	3	70
19	New physiopathological and therapeutic approaches to diverticular disease of the colon. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 299-307	4	44
18	Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. <i>Medical Science Monitor</i> , 2007 , 13, CR187-90	3.2	20
17	Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 312-6	3	98
16	Peripheral neurological disturbances, autonomic dysfunction, and antineuronal antibodies in adult celiac disease before and after a gluten-free diet. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1869-74	4	40
15	Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 461-5	4	2
14	Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. <i>Medical Science Monitor</i> , 2006 , 12, PI29-32	3.2	25
13	Mesalazine for diverticular disease of the colon--a new role for an old drug. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 69-74	4	20
12	High prevalence of celiac disease among patients affected by Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 662-6	4.5	45
11	Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. <i>World Journal of Gastroenterology</i> , 2005 , 11, 2773-6	5.6	47
10	Factors influencing lactose intolerance. <i>European Journal of Clinical Investigation</i> , 2004 , 34, 314-5; author reply 316	4.6	8
9	Acute diverticulitis of the colon--current medical therapeutic management. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 55-9	4	37
8	Gastrointestinal motility disturbances in celiac disease. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 642-5	3	47
7	Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 360-3	3	47
6	Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. <i>Medical Science Monitor</i> , 2004 , 10, PI126-31	3.2	118
5	Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. <i>Medical Science Monitor</i> , 2004 , 10, CR662-6	3.2	44

4	Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. <i>Journal of Clinical Gastroenterology</i> , 2003 , 37, 387-91	3	72
3	Assessment of oro-caecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 69-74	2.2	34
2	Prevalence of anti-tissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 219-21	3	125
1	Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first- or second-line therapy to cure <i>Helicobacter pylori</i> infection. <i>Hepato-Gastroenterology</i> , 2002 , 49, 1006-9		2